Sichuan Goldstone Asia Pharmaceutical Inc. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 731.93 million compared to CNY 484.27 million a year ago. Revenue was CNY 731.93 million compared to CNY 484.27 million a year ago. Net income was CNY 80.94 million compared to net loss of CNY 95.15 million a year ago. Basic earnings per share from continuing operations was CNY 0.2 compared to basic loss per share from continuing operations of CNY 0.24 a year ago. Diluted earnings per share from continuing operations was CNY 0.2 compared to diluted loss per share from continuing operations of CNY 0.24 a year ago.